Tandem Diabetes Care Inc (NASDAQ:TNDM) has earned a consensus rating of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $11.30.
Several brokerages have weighed in on TNDM. Zacks Investment Research cut shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Friday. Oppenheimer reissued a “buy” rating on shares of Tandem Diabetes Care in a research note on Thursday. Robert W. Baird raised shares of Tandem Diabetes Care from a “neutral” rating to an “outperform” rating in a research note on Friday. ValuEngine cut shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Finally, Cowen reissued a “hold” rating on shares of Tandem Diabetes Care in a research note on Tuesday, February 27th.
In related news, CEO Kim D. Blickenstaff purchased 750,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were acquired at an average cost of $2.00 per share, with a total value of $1,500,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher J. Twomey purchased 75,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $150,000.00. The disclosure for this purchase can be found here. Insiders have bought 850,539 shares of company stock worth $1,749,091 over the last three months. 20.90% of the stock is owned by insiders.
Shares of TNDM stock opened at $3.99 on Friday. The company has a debt-to-equity ratio of -2.63, a current ratio of 1.78 and a quick ratio of 1.03. Tandem Diabetes Care has a 52 week low of $2.14 and a 52 week high of $13.00.
Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, March 1st. The medical device company reported ($1.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.13). The business had revenue of $40.00 million for the quarter, compared to analysts’ expectations of $38.41 million. The company’s revenue was up 61.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.48) earnings per share. analysts forecast that Tandem Diabetes Care will post -1.41 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Tandem Diabetes Care Inc (TNDM) Receives Consensus Rating of “Hold” from Analysts” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3295751/tandem-diabetes-care-inc-tndm-receives-consensus-rating-of-hold-from-analysts.html.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.